RMRK
8.6.2021 15:32:07 CEST | Business Wire | Press release
RMRK , an advanced NFT protocol project, announced today that it raised 6 million USD to build the standard cross-chain NFT infrastructure in the Polkadot and Kusama ecosystem. Investors such as D1 Ventures , YBB , PAKA , DFG , and others are all betting on NFTs 2.0 as presented by RMRK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005768/en/
“NFTs right now are digital-dust-gathering assets, mainly overpriced digital pictures that you keep in your digital wallet until the next NFT hype wave hits.” says Bruno Škvorc, project founder and Web3 Foundation alum. “We believe that they’re meant for much more than that. NFTs can have long lasting liquidity by being upgradable, nestable within other NFTs, by being able to react to people reacting to them with emotes, and by being democratically governed through fractional ownership!”
By launching a gamified “initial collectible offering” called Kanaria on Kusama even without smart contracts, the RMRK team has pioneered the NFT-crowdfunding approach which netted them a total of 2 million USD in limited edition egg-nft sales. All egg buyers will also be entitled to a fairdrop of the coming $RMRK token. The remaining 4 million were raised directly from investors based on the vision of NFTs 2.0.
NFTs 2.0
RMRK is developing new standards to expand what NFTs can do:
● NFTs that can own other NFTs
● NFTs that can listen to commands or issue them to their children
● NFTs as DAOs that can, through fractional ownership, be controlled by a group
● NFTs that can react to emotion with conditional rendering logic (send 50 rocket emoji to a picture of a moon, and it can show you a moonbase)
● NFTs that can have multiple resources at once (mint an e-book with an audio version, a PDF file, and a high resolution cover - the environment it’s loaded in decides which part to load automatically).
With these “art legos” in place, RMRK has created an NFT operating system that makes possible NFT projects of arbitrary complexity .
Powerful Partnerships
This potential of art legos was recognized by key players in the Kusama and Polkadot ecosystem, as documented on RMRK’s official blog . Rather than crowd the already crowded parachain space, RMRK has opted to add their technology to other chains instead - the project’s very first runtime-based deployment will be with Unique Network , a dedicated NFT parachain project in the Kusama and Polkadot ecosystem.
With RMRK’s logic coming into the runtime functionality of several partner chains, the RMRK standards for NFTs 2.0 are poised to become the first shared-runtime environment in the Polkadot ecosystem, allowing for seamless teleportation of non fungible assets to and from any supported chain, natively, and at almost zero cost.
You can learn more about RMRK at rmrk.app , and you can play around with their official minting and trading UI for NFTs called Singular on singular.rmrk.app . Reach out to the team at hello@rmrk.app , on Telegram , or on Twitter , and read their blog on Subsocial .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005768/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
